Adrenomyeloneuropathy Market Size in the 7MM accounted for ~ USD 9.26 million in 2024 and is estimated to grow with a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Adrenomyeloneuropathy Market Insights, Epidemiology, and Market Forecast- 2034′′ report offers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Unlock key insights into the Adrenomyeloneuropathy Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Adrenomyeloneuropathy Market Report
• In November 2025, Minoryx Therapeutics S.L. conducted a Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
• The total diagnosed cases of Adrenomyeloneuropathy in the US were around 1,000 cases in 2024.
• Germany had the highest diagnosed prevalent cases of Adrenomyeloneuropathy among the EU4 and the UK, accounting for more than 27% of cases in 2024.
• In 2024, the total treated cases of Adrenomyeloneuropathy in Japan were around 433.
• The leading Adrenomyeloneuropathy Companies such as Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others.
• Promising Adrenomyeloneuropathy Therapies such as Leriglitazone (MIN-102), SBT101, VK0214, and others

Stay ahead in the competitive landscape of the Adrenomyeloneuropathy Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adrenomyeloneuropathy Epidemiology Segmentation in the 7MM
• Total Prevalence of Adrenomyeloneuropathy
• Prevalent Cases of Adrenomyeloneuropathy by severity
• Gender-specific Prevalence of Adrenomyeloneuropathy
• Diagnosed Cases of Episodic and Chronic Adrenomyeloneuropathy

Download the report to understand which factors are driving Adrenomyeloneuropathy epidemiology trends @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adrenomyeloneuropathy Emerging Therapies

• Leriglitazone (MIN-102): Minoryx Therapeutics
Leriglitazone (MIN-102) is an investigational novel, orally bioavailable, and selective PPAR gamma agonist with a superior profile for CNS-related diseases. Minoryx Therapeutics has announced the publication of data from its Phase II/III ADVANCE trial evaluating leriglitazone in male patients with adrenomyeloneuropathy. While the trial did not meet its primary endpoint, the results demonstrated promising signs of efficacy. Leriglitazone showed potential in stabilizing disease progression, with improvements in body sway and positive effects on key biomarkers. Notably, the treatment led to a reduction in neurofilament light levels and helped preserve blood-brain barrier integrity, indicating a potential neuroprotective effect. Liraglutide received Fast Track Designation from the FDA for the treatment of all forms of X-ALD, including Adrenomyeloneuropathy and cCALD.

• SBT101: Spur Therapeutics
SBT101 is the first investigational AAV-based gene therapy developed to counteract ABCD1 mutations in adrenomyeloneuropathy (Adrenomyeloneuropathy). It aims to restore ABCD1 expression and reduce very long-chain fatty acid (VLCFA) levels, targeting the underlying cause of the disease. Using an adeno-associated virus (AAV) capsid, SBT101 delivers a functional ABCD1 gene directly to spinal cord cells to restore cellular function and slow disease progression. Preclinical studies have shown dose-dependent improvements in Adrenomyeloneuropathy disease markers in mouse models and favorable tolerability in non-human primates at six months post-treatment. SBT101 also demonstrated increased ABCD1 expression and reductions in toxic substrates in the spinal cord. SBT101 is currently being evaluated in a Phase I/II first-in-human clinical trial.

Adrenomyeloneuropathy Therapies and Companies
• Leriglitazone (MIN-102): Minoryx Therapeutics
• SBT101: Spur Therapeutics
• VK0214: Viking Therapeutics

Discover the future of Adrenomyeloneuropathy treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Adrenomyeloneuropathy Market Drivers
• Rising diagnosed prevalence across major markets, increasing the potential patient pool.
• Growing awareness and improved genetic testing, enabling earlier and more accurate diagnosis of X-ALD and AMN.
• Advancements in research and development, including gene therapies and novel small molecules showing promising clinical outcomes.
• Increased investment by pharmaceutical companies driven by the unmet medical need and orphan drug incentives.
• Supportive regulatory frameworks, such as fast-track and orphan drug designations, accelerating therapy development.

Adrenomyeloneuropathy Market Barriers
• Lack of approved treatments, limiting therapeutic options and slowing market expansion.
• Complex disease biology, making drug development challenging and time-consuming.
• High cost of advanced therapies like gene therapy, potentially restricting accessibility.
• Limited awareness in some regions, resulting in underdiagnosis or delayed diagnosis.
• Small patient population, reducing commercial attractiveness and affecting investment in large-scale trials.

Adrenomyeloneuropathy Market Outlook
The Adrenomyeloneuropathy market is gradually evolving, though current pipeline activity remains relatively limited, particularly given the high unmet needs among patients. Key industry players, including Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others, are actively advancing their lead candidates through various stages of clinical development. Despite this progress, the Adrenomyeloneuropathy market faces several hurdles, including a general lack of disease awareness, reimbursement limitations, and ongoing concerns about the efficacy of available Adrenomyeloneuropathy treatments. However, the market is expected to expand over the coming years, driven by a growing patient population, increased research funding, and continuous advancements in therapeutic options. Further momentum is likely to come from improved diagnostic techniques, preventive strategies, and efforts to enhance patient education and awareness.

Explore the dynamics of the Adrenomyeloneuropathy Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Adrenomyeloneuropathy Market Report
• Study Period- 2020-2034
• Coverage: 7MM
• Adrenomyeloneuropathy Companies- Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others.
• Adrenomyeloneuropathy Therapies- Leriglitazone (MIN-102), SBT101, VK0214, and others
• Adrenomyeloneuropathy Therapeutic Assessment: Adrenomyeloneuropathy current marketed and Adrenomyeloneuropathy emerging therapies
• Adrenomyeloneuropathy Market Dynamics: Adrenomyeloneuropathy market drivers and Adrenomyeloneuropathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Adrenomyeloneuropathy Unmet Needs, KOL's views, Analyst's views, Adrenomyeloneuropathy Market Access and Reimbursement

Table of Contents
1. Adrenomyeloneuropathy Market Report Introduction
2. Executive Summary for Adrenomyeloneuropathy
3. SWOT analysis of Adrenomyeloneuropathy
4. Adrenomyeloneuropathy Patient Share (%) Overview at a Glance
5. Adrenomyeloneuropathy Market Overview at a Glance
6. Adrenomyeloneuropathy Disease Background and Overview
7. Adrenomyeloneuropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Adrenomyeloneuropathy
9. Adrenomyeloneuropathy Current Treatment and Medical Practices
10. Adrenomyeloneuropathy Unmet Needs
11. Adrenomyeloneuropathy Emerging Therapies
12. Adrenomyeloneuropathy Market Outlook
13. Country-Wise Adrenomyeloneuropathy Market Analysis
14. Adrenomyeloneuropathy Market Access and Reimbursement of Therapies
15. Adrenomyeloneuropathy Market Drivers
16. Adrenomyeloneuropathy Market Barriers
17. Adrenomyeloneuropathy Appendix
18. Adrenomyeloneuropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.